- Home
- ZGN vs CNTA Comparison
ZGN vs CNTA Comparison
Compare ZGN & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZGN | CNTA |
|---|---|---|
| Founded | 1910 | 2020 |
| Country | Italy | United Kingdom |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZGN | CNTA |
|---|---|---|
| Price | $10.71 | $22.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $10.98 | ★ $37.70 |
| AVG Volume (30 Days) | 506.9K | ★ 1.3M |
| Earning Date | 09-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $2,248,050,499.00 | $15,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.87 | N/A |
| P/E Ratio | $23.98 | ★ N/A |
| Revenue Growth | N/A | ★ 118.88 |
| 52 Week Low | $6.05 | $9.60 |
| 52 Week High | $11.00 | $30.58 |
Technical Indicators
Market Signals| Indicator | ZGN | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 58.44 | 30.17 |
| Support Level | $10.20 | $22.15 |
| Resistance Level | $10.48 | $26.01 |
| Average True Range (ATR) | 0.22 | 1.04 |
| MACD | -0.00 | -0.37 |
| Stochastic Oscillator | 91.38 | 11.88 |
Price Performance
Historical ComparisonAbout ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.